Despite the widespread use of liposome-mediated gene transfer in cancer therapy protocols, little is known about the tissue distribution of intralesionally administered DNA. We have previously shown that antisense gene therapy targeting the epidermal growth factor receptor (EGFR) inhibited tumor growth in a human head and neck squamous cell carcinoma (HNSCC) xenograft model. Further investigation demonstrated lack of systemic toxicity with intramuscular or intratumoral administration of this liposomal-DNA complex. In the present study, we compared two approaches to determine the presence of exogenous DNA in the plasma and tissues of mice treated with intramuscular injection of EGFR antisense gene therapy. PCR analysis using genomic DNA plus plasmid DNA as template was 83-fold more sensitive than PCR using a mixture of total RNA and plasmid DNA as template. With the more sensitive method (able to detect fewer than 500 molecules of EGFR antisense DNA in 1 mg of genomic DNA), foreign DNA was detected in all organs up to 1 month following a single injection. In contrast, using RNA plus plasmid DNA as template, exogenous DNA was only detected at the injection site at 1 week, and was undetectable at 1 month. Optical imaging studies demonstrated plasmid DNA only at the injection site. Although less sensitive than PCCR, Southern blot hybridization showed no evidence of integration of foreign DNA into the host genome in vitro or in vivo. These results emphasize the importance of defining the assays used to detect foreign DNA and suggest that the ability to detect intralesionally administered liposomal gene therapy, in organs distant from the injection site, is directly correlated with the sensitivity of the method employed.
H ead and neck squamous cell carcinoma (HNSCC) is a fatal disease whose incidence is increasing worldwide. Despite advances in cancer therapy, conventional treatment of locally or regionally advanced HNSCC has produced long-term survival in less than one-third of patients, with a high risk of regional and, to a lesser extent, distant recurrence. 1, 2 Innovative approaches are required to improve the local control and overall survival of HNSCC patients.
The epidermal growth factor receptor (EGFR) is upregulated in the vast majority of HNSCC tumors where EGFR levels correlate with survival, independent of other clinical and pathologic parameters, including nodal staging. 3 Cumulative evidence suggests that overexpression of EGFR plays a significant role in the development and progression of many epithelial cancers, including HNSCC. A variety of strategies have been developed to target selectively EGFR including monoclonal antibodies, ligand-linked immunotoxins, tyrosine kinase-specific inhibitors and antisense approaches. 4 We previously demonstrated the growth inhibitory effects of EGFR antisense oligonucleotides in HNSCC cells in vitro. 5 In vivo, we reported the antitumor effects of an EGFR antisense sequence expressed under the control of the U6 small nuclear RNA promoter, complexed with DC-chol liposomes, and administered intratumorally into a HNSCC xenograft model. 6 Further investigation demonstrated no evidence of organ toxicity associated with intralesional administration of this EGFR antisense gene therapy formulation.
Previous studies evaluating the tissue distribution of liposome/DNA complexes in vivo have utilized polymerase chain reaction (PCR) amplification to detect exogenous DNA in tissues. 8 These earlier reports found widespread tissue distribution of plasmid DNA after systemic or intratumoral routes of administration of liposome-DNA complexes. Using a protocol capable of detecting one copy of DNA per 10 5 cells, others found evidence of foreign DNA in the treated tumor, but not in the serum, 3-7 days after the last injection. 9 Using a PCR assay that could detect a range of 250-16,000 copies of plasmid DNA per microgram of genomic DNA, others have reported the presence of plasmid DNA in all tissues examined 28 days post-DNA-liposome injection. 10 In another study, mice bearing human ovarian cancer xenografts were treated weekly with a liposome/DNA formulation for 4 months via intratumoral injections. 11 Using an assay that was limited to detecting 1 ng of plasmid in 0.5 mg of genomic DNA, integrated plasmid DNA was detected in the lung and kidney of the mice that survived up to one and a half years after the last dose. To date, most studies have used nonuniform methods to detect DNA or provided limited information regarding the sensitivity of the specific PCR detection method employed.
In the present investigation, the sensitivity of the two methods to determine the presence of EGFR antisense DNA at the injection site and in organs distant from the injection site was evaluated in mice administered the starting dose used in the ongoing phase I clinical trial in HNSCC patients. Complementary information was derived from optical imaging studies of the injected tumor and distant organs, as well as Southern blot analysis to determine the localization and integration of foreign DNA at distant anatomic sites.
Methods

Plasmid vector
The pNGVL-1 expression vector (National Gene Vector Laboratory, University of Michigan, MI) was modified to contain a 39 bp EGFR fragment in the antisense orientation (5 0 -TCG AGC CGG CCG TCC CGG AGG GTC GCA TCG CTG CTC CCC GAA GAT GCA-3 0 ). The antisense EGFR insert used for cloning was derived from a pGEM plasmid backbone as described previously. 6 The U6 expression cassette include a U6 promoter, enhancer, mutated U6 structural sequence and U6 terminator. The antisense EGFR insert was cloned into the pNGVL vector at the SpeI restriction site resulting in the plasmid pNGVL-U6-EGFR antisense (Fig 1) . The vector contained a kanamycin resistance Figure 1 Construction of the EGFR antisense gene therapy plasmid, pNGVL-EGFR antisense. The entire U6 expression cassette was excised from pDHU6-EGFR antisense plasmid vector with SpeI and inserted into the plasmid vector pNGVL-1 at the SpeI site in the multiple cloning region. 25 (a) Schematic representation of the U6 expression cassette. The expression cassette contains a U6 enhancer, a modified U6 promoter, a 39 bp antisense EGFR DNA fragment, the first six and the last 18 nucleotides of the U6 structure sequence and the 3 0 untranslated region of U6 gene. marker that had been previously approved for use in human trials.
DNA-liposome formulation
EGFR antisense DNA was prepared by bacterial fermentation and extracted with a plasmid Giga kit (QIAGEN, Valencia, CA). DC-chol, 3a-[n-(n 0 , n 0 -dimethylaminoethane)-carbamoyl] cholesterol hydrochloride, was prepared with DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine with a ratio of 3:2, to generate cationic liposomes that were used to enhance gene delivery and were manufactured as previously described. 12 The EGFR antisense DNA-liposome complex was prepared under aseptic conditions on the day of treatment. For in vivo studies, a mixture of 5% (w/v) glucose and 1 nmol of liposomes per microgram of antisense DNA was prepared in sterile distilled water immediately before injection.
Cells
The 1483 cell line is a well-characterized HNSCC cell lines derived from a tumor of the retromolar trigone. 13 In culture, the cells were maintained in Dulbecco 0 s modification of Eagle 0 s medium (DMEM) (Fisher Scientific Co:, Pittsburgh, PA) supplemented with 10% fetal calf serum (FCS) and PNS antibiotics (Life Technologies, Inc. (GIBCO BRL), Gaithersburgh, MD).
In vivo studies
HA/ICR male and female mice (4-6 weeks old) were purchased from Taconic Farms Inc. (Germantown, NY). Animals were housed, cared for and used in accordance with institutional guidelines. On arrival, the mice were quarantined for 2 weeks before treatment to allow for acclimatization and to ensure that the mice were free of infections. The animals were then randomly divided into five groups. Tissue distribution determinations were performed at five different time points (48 hours, 1 week, 2 weeks, 3 weeks and 4 weeks) after a single intramuscular injection of the plasmid:liposome complex. Each group included three male and three female mice treated with a single injection of EGFR antisense DNA plus liposomes. A male and a female mouse injected with saline were used as controls in each group. Each mouse was injected intramuscularly with a single dose of the EGFR antisense DNA/liposome complex (60 mg DNA plus 60 nmol DCchol/DOPE liposomes) in the left gastrocnemius muscle. This dose was established as the initial intratumoral starting dose for an ongoing phase I clinical trial in head and neck cancer patients and was equivalent to approximately 175 mg (calculated as mg/kg for an average 70 kg adult). The experiment was repeated to ensure reproducibility of the results.
In a separate experiment, nude mice were injected subcutaneously with 1483 cells (10 6 cells in 100 ml). After 10 days, when the tumors were palpable and had attained a total volume of 0.065 cm 3 , a single intratumoral injection of pNGVL-U6-EGFR antisense/liposome complex (25 mg DNA with 25 nmol of DC-chol/DOPE) was administered. The mice were killed and the tumors were excised 24 hours 1 week and 1 month post injection. Tumors that were not injected with the DNA-liposome complex served as controls and were harvested at 1 week and 1 month along with injected tumors. Harvested tumors were snap-frozen in liquid nitrogen. Genomic DNA was extracted from the tumors using the Puregene DNA isolation kit (Gentra Systems) according to the manufacturer 0 s protocol. For analysis by Southern blotting, approximately 30 mg of genomic DNA was digested overnight with 30 U Eco RI restriction enzyme at 371C. Plasmid DNA digested with EcoRI was run on every gel as a positive control. To detect the sensitivity of the Southern blot, 30 mg of genomic DNA was spiked with varying amounts of plasmid DNA and subjected to restriction enzyme digestion. The digested DNA was resolved on a 0.7% agarose gel in the presence of 0.5 mg/ ml ethidium bromide at 20 V for 16 hours. The gel was photographed, transferred onto a nylon membrane and Southern blot hybridization was carried out as described previously.
14 The blot was probed with a 32 P-labeled antisense EGFR fragment (39 bp). Labeling was carried out using the random primer labeling kit (Roche, Germany) according to the manufacturer 0 s instructions.
Tissue collection
Animals were killed at various time points after treatment. Plasma and soft tissues from the immunocompetent mice were harvested and snap-frozen including brain, heart, lung, liver, kidney, left and right gonads (testis/ ovary), left (treated) and right (contralateral) gastrocnemius muscle, and the left (ipsilateral) and right (popliteal) draining lymph nodes. All tissues were stored at À801C immediately after harvesting until nucleic acid extraction. Care was taken to use separate instruments for the harvest of each organ from each mouse to avoid cross contamination from exogenous plasmid DNA. The injection site was harvested last in all cases.
Isolation of RNA and plasmid DNA from tissues and plasma
Finely minced tissues and plasma were subjected to total RNA and plasmid DNA isolation using the Ultraspec RNA reagent (Biotech Laboratories, Houston, TA) that releases total nucleic acid from the starting material. Following the manufacturer 0 s recommendation, samples were extracted with chloroform to remove protein and genomic DNA. RNA and plasmid DNA were precipitated and washed with 70% ethanol. The precipitated nucleic acid was purified and resolved in distilled water. Total nucleic acid in the samples was quantified by measuring the optical density at a wavelength of 260 nm using a spectrophotometer (Amersham Pharmacia Biotech, Piscataway, NJ). The ratio of the optical densities at 260 and 280 nm was determined to verify the purity of the sample nucleic acid preparation.
Isolation of genomic DNA plus plasmid DNA from tissues
Genomic DNA plus plasmid DNA was isolated from the harvested tissues using the PUREGENE DNA isolation kit (Minneapolis, MN). Briefly, tissues were finely minced, lysed and the samples were treated with proteinase K (20 mg/ml at 551C overnight) and RNase A (371C for 60 minutes). Protein was removed by a protein precipitation solution. DNA was precipitated with isopropanol and subjected to microcentrifugation. The DNA pellet was washed in 70% ethanol, air dried, resolved in DNA hydration solution and quantified by measuring the absorbency at 260 nm. A ratio of the optical densities at 260 and 280 nm was determined to evaluate the purity of the sample nucleic acid preparation.
DNA extraction from plasma
Plasma (100 ml) was diluted with 200 ml TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) and treated with 0.3 mg/ml proteinase K at 601C for 2 hours followed by phenol:-chloroform extraction. After isopropanol precipitation and two ethanol washes, the DNA was resuspended in 20 ml of distilled water.
Plasmid DNA detection method
Plasmid DNA was detected in different tissues using the PCR. The PCR primers (primer set A) were designed as follows: the forward primer 5 0 -AAA CGC ACC ACG TGA CGG-3 0 targeted the U6 promoter and the reverse primer 5 0 -CTT CGG GGA GCA GCG ATG-3 0 bound to the end of the antisense insert in the construct (Fig 1) . This pair of primers could specifically amplify only the pNGVL-EGFR antisense DNA and not endogenous U6 or EGFR genes. The size of the PCR product obtained was 372 bp. To determine the role of primer design/ location, an alternative set of PCR primers were generated 16 bp upstream of the first primer set. The forward primer 5 0 -TGG AAA GAC GCG CAG GCA-3 0 targeted the U6 promoter and the reverse primer 5 0 -GCG ACC CTC CGG GAC GGC-3 0 bound to the start (5 0 end) of the antisense insert in the construct. To determine the integrity of the DNA used for PCR analysis, the DNA samples were subjected to PCR using b-actin primers. The sequence of the forward primer used was 5 0 -GGC GGC ACC ACC ATG TAC CCT-3 0 and that of the reverse primer was 5 0 -AGG GGC CGG ACT CGT CAT ACT-3 0 . The size of the PCR product obtained was 202 bp. The same conditions used to amplify EGFR antisense DNA was used to amplify b-actin in the samples.
Sensitivity of methods used to detect EGFR antisense DNA
PCR detection was performed with total RNA plus plasmid DNA or genomic DNA plus plasmid DNA. To determine the sensitivity of each method, nucleic acid preparations from control animals not treated with the gene therapy formulation were spiked with known concentrations of plasmid DNA and subjected to PCR analysis. Serial dilutions containing 6.55 Â 10 À4 to 6.55 Â 10 À9 mg (equivalent to 1.25 Â 10 8 to 1.25 Â 10 3 molecules) of pNGVL-U6-EGFR antisense DNA per micro liter were prepared. Each diluent (1 ml) was mixed with 3 mg of total RNA extracted from the negative control mouse tissues and subjected to PCR amplification. To evaluate the sensitivity of the PCR method using DNA as template, 10-fold serial dilutions of pNGVL-U6-EGFR antisense DNA from 2.62 Â 10 À7 to 2.62 Â 10 À11 mg/ml (equivalent to 50,000 to 5 molecules/ml) were prepared. Each diluent (1 ml) was mixed with 1 mg of genomic DNA extracted from the control tissues and subjected to PCR amplification. PCR amplification was carried out in a total reaction volume of 25 ml containing the templates (3 mg of total RNA or 1 mg of genomic DNA or 5 ml of plasma extract), 1 U of Taq polymerase (GIBCO BRL, Grand Island, NY), and 0.4 mM of each primer, 0.1 mM dNTPs, and 2 mM Mg 2+ . Following a hot start at 941C for 2 minutes, amplification of the plasmid DNA was achieved using the following conditions: 941C for 30 seconds, 581C for 30 seconds and 721C for 30 seconds per cycle for a total of 40 cycles. After amplification, 12.5 ml of the PCR products were electrophoresed on a 1.5% agarose gel containing 0.5 mg/ ml ethidium bromide along with a standard molecular weight marker (100 bp DNA ladder). The PCR products were visualized and photographed using a 254 nm UV transilluminator.
Determination of integration using Southern blot hybridization
A representative SCCHN cell line, 1483, was transiently transfected with pNGVL-U6-EGFR antisense DNA. Following the manufacturer 0 s instructions, 2 mg of plasmid DNA and 10 ml of GenePorter transfection reagent (Gene Therapy Systems, CA) were applied to each well of a six-well plate containing 5 Â 10 5 cells per well. Cells were harvested and genomic DNA was isolated 3, 5 and 7 days post-transfection. To determine the presence of exogenous DNA in vivo, tumors from mice treated with pNGVL-U6-EGFR antisense DNA plus liposomes were analyzed using Southern blot hybridization. Tumors were harvested 1 day, 1 week and 1 month after a single injection. Genomic DNA was extracted according to the manufacturer 0 s protocol (Puregene, Genetech). Approximately 30 mg of genomic DNA from injected tumors or transfected cells was digested with EcoRI (10 U/ml at 371C overnight), run on an 1% agarose gel, blotted to a nitrocellulose membrane and hybridized with 32 P-labeled pNGVL-U6-EGFR antisense DNA using a standard Southern hybridization protocol.
14 To determine the sensitivity of Southern blot analysis, genomic DNA from tissues of control mice was spiked with concentrations of plasmid DNA ranging from 1 to 200 ng. Genomic DNA extracted from lung of pNGVL-U6-EGFR antisense injected mice (1 month time point) was digested with EcoRI, electrophoresed on an agarose gel, and subjected to Southern hybridization.
Intracellular localization of EGFR antisense DNA
To determine the intracellular localization of the EGFR antisense gene after intratumoral injection, we examined fluorescein-labeled DNA in tumors and gonads using fluorescence microscopy. The DNA was labeled with the Labet IT fluorecein nucleic acid labeling kit (Molecular Probes, Eugene, OR). Every 5 mg of DNA was mixed with 5 ml of reconstituted labeling reagent in a 50 ml reaction performed at 371C for 1 hour followed by a purification with a G50 spin column. The labeling reaction was scaled up according to the requirements of each experiment and condensation of DNA was performed by ethanol precipitation. Established HNSCC xenografts were injected once with a DNA-liposome mixture of 25 mg-labeled DNA and 25 nmol DC-chol liposomes. Tumors and gonads were harvested 2 weeks after a single intratumoral injection. Tissue samples were fixed in 2% paraformaldehyde in PBS for 1 hour at 41C, cryoprotected in 30% sucrose overnight and shock-frozen in liquid nitrogencooled isopentane. Sections (5 mm) were cut on to glass slides using a Microm (Walldorf, Germany) 505E cryostat and counterstained with DAPI (1 mg/100 ml) for 2 minutes. The sections were mounted in glycerol and examined using an Olympus (Melville, NY) 1X70 microscope with a Â 40 planapochromat oil immersion objective and a double pass (green/blue) cube. Images were captured using an Optronics Firewire camera (Galeta, CA) and stored.
Results
PCR detection sensitivity
Two strategies were designed to detect the EGFR antisense DNA in tissue samples using PCR. Plasmid DNA can theoretically be localized in the extracellular compartment, in the cytoplasm or in the nucleus (unintegrated or integrated). The first approach involved isolation of total RNA from cells. Using this method, the cells were lysed and chromosomal DNA was removed. Therefore, plasmid DNA (if any) would be isolated if localized to the extracellular space, or unintegrated in the cytoplasm or nucleus. Specifically, any small molecular weight DNA present in the cytoplasm was presumably extracted along with the RNA and could serve as a template in subsequent amplification reactions. The first method was used prior to the death of the patient on a gene therapy trial at the University of Pennsylvania. As a result of this death, new requirements were implemented by the FDA for PCR sensitivity to detect distribution of therapeutic DNA. In response to these requirements, we devised a more stringent method. Although more time consuming, the second strategy utilized a genomic DNA isolation process that lysed the cells and digested away the RNA, thus obtaining plasmid DNA (if any) that localized to the extracellular space, the cytoplasm, or the nucleus in integrated or unintegrated form. The cellular DNA was precipitated from solution and centrifuged so that in addition to genomic DNA, extra chromosomal plasmid DNA was also extracted. This DNA mixture (a combination of genomic and plasmid DNA) was then used as a template in the PCR reaction. The relative sensitivity of these two PCR detection procedures was evaluated. When using total RNA as input, the PCR amplification could detect as little as 1.25 Â 10 5 copies of pNGVL-U6-EGFR antisense molecules in every 3 mg of total RNA (Fig 2a) . The sensitivity of the PCR detection was increased approximately 83-fold when using genomic DNA as input. With the second method, we could detect as little as 500 copies of EGFR antisense DNA per microgram of genomic DNA (Fig 2b) . The higher sensitivity of the second method is most likely because of the increased amount of starting material (DNA) and the possibility that the mixture of RNA and DNA used in the first method might inhibit the sensitivity of the PCR assay.
All PCR reactions to determine the tissue distribution of the EGFR antisense plasmid were run with positive controls as shown in Figure 3 . When using total RNA as input, 1.25 Â 10 5 copies of pNGVL-U6-EGFR antisense À9 mg/ml) was mixed with 3 mg of total RNA extracted from kidneys in the untreated mice, respectively, and a series of PCR reactions were performed with these combinations of templates. As shown in the representative agarose gel, the PCR reaction was able to amplify 1.25 Â 10 5 copies of the plasmid DNA when mixed with 3mg of total RNA. (b) Using genomic DNA plus plasmid DNA as input, 1 ml of each 10-fold serial diluent (50,000 to five copies of pNGVL-U6-EGFR antisense per microliter, equivalent to 2.62 Â 10 À7 -2.62 Â 10 À11 mg/ml) was mixed with 1 mg of genomic DNA extracted from kidneys harvested from untreated control mice, respectively, and a series of PCR reactions were carried out with these combinations of templates. As shown in the representative agarose gel, the PCR was able to amplify 500 copies of the plasmid DNA when mixed with 1 mg of genomic DNA.
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was mixed with 3 mg of RNA from untreated mice as controls. Alternatively, 500 copies of the plasmid DNA was mixed with 1 mg of genomic DNA from untreated control mice when the PCR assay was run using genomic DNA plus plasmid DNA as starting material. Using these controls, all PCR detection reactions reached the expected sensitivities (1.25 Â 10 5 and 500 copies, respectively).
EGFR antisense DNA is only detected in mice treated with gene therapy
Primers used in all PCR reactions were designed to target the region linking the U6 promoter and the EGFR antisense sequence in the pNGVL-U6-EGFR antisense vector (Fig 1) . Thus, amplification of only pNGVL-U6-EGFR antisense DNA was achieved generating a 372 bp PCR product without interference from endogenous U6 or EGFR genes. The primers were tested in a PCR reaction with the templates extracted from control mouse tissues (untreated) and no PCR product was detected in these negative controls (data not shown). Samples extracted at the same time point from each tissue type were examined in the same PCR reaction. Each PCR reaction included two negative controls (samples extracted from the untreated mice) to verify that the PCRamplified products were only detected in tissues from mice injected with EGFR antisense DNA (Fig 3) .
EGFR antisense DNA detection is associated with the sensitivity of the PCR method employed
Using total RNA plus plasmid DNA as input, we examined the tissue distribution of intramuscular administration of a single dose of EGFR antisense DNA (60 mg) plus DC-chol/DOPE liposomes (60 nmol). At 48 hours after EGFR antisense DNA injection, plasmid DNA was detected at the injection site (4/6 mice), the contralateral injection site (5/6 mice), brain (4/6 mice) and lung (2/6 mice). At 1 week, the DNA was only detected at injection site (2/6 mice) and it was undetectable at all sites examined at 1 month (Fig 4) . Plasma from all mice and tissues harvested from control (untreated) mice showed no evidence of EGFR antisense DNA at all time points examined (data not shown).
Utilizing the more sensitive PCR detection method with genomic DNA plus plasmid DNA as input (able to detect less than 500 copies of plasmid DNA in 1 mg genomic DNA), EGFR antisense DNA was detected in most of the organs harvested at each time point. The presence of EGFR antisense DNA could not be detected in the plasma at any of the time points examine (Fig 5) . The results at each time point after a single intramuscular injection are listed in Table 1 .
To determine the role of primer design and location, PCR analysis was repeated using a second set of primers (primer set B). EGFR antisense DNA was successfully amplified with the second set of primers. The pattern of amplification obtained was similar to the PCR product obtained wit the first primer (primer set A) (Fig 6) . This suggest that the PCR results are not primer specific. To determine the integrity of the template DNA, DNA from tissues was subjected to PCR with b-actin primers. The DNA extracted was found to be of good quality and amplification of b-actin was detected in all samples.
EGFR antisense DNA is not integrated into host genomic DNA
One of the major safety concerns of gene therapy is the potential for integration of foreign DNA into the host genome. The PCR-based assay could not determine if the therapeutic DNA had been intergrated. To address this possibility, a representative HNSCC cell line 1483 was 2 and 3) demonstrate the specificity of the reaction using DNA extracted from untreated control mice. Positive controls included 1000 copies of pNGVL-U6-EAS (lane 12) and DNA extracted from the untreated control mice (the same as lanes 2 and 3) mixed with 1000 copies of pNGVL-U6-EGFR antisense DNA (lanes 10 and 11). This PCR reaction condition can detect as few as 500 copies of pNGVL-U6-EGFR antisense DNA per microgram of genomic DNA. Figure 4 Distribution of the EGFR antisense plasmid DNA in total RNA plus plasmid DNA extracted from tissues. Ethidium bromidestained agarose gels of PCR reaction products from organs harvested from treated mice at several time points. At 48 hours after EGFR antisense DNA injection, plasmid DNA was detected at the injection site (4/6), the muscle contralateral to the site of injection (5/ 6), brain (4/6) and lung (2/6). At 1 week, the DNA was only detected at the injection site (2/6) and it was undetectable in any organ at 1 month.
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transiently transfected with pNGVL-U6-EGFR antisense DNA. The efficiency of this transient transfection was approximately 30% as determined with a b-galactosidase expression construct (data not shown). As shown in Figure 7a , no integration of plasmid DNA into the host genome was detected 3, 5 or 7 days post-transfection. To determine whether or not intratumoral administration of EGFR antisense gene therapy resulted in integration of this exogenous DNA into the host genome, Southern blot hybridization was carried out on DNA extracted from treated tumors. At all time points examined (1 day, 1 week or 1 month) after a single intratumoral injection, there was no evidence of EGFR antisense DNA integration in these representative tumors (Fig 7b,c) . The inability to detect integration of exogenous DNA using Southern blot analysis may be due in part to the relative sensitivity of this detection method compared with PCR. To determine the sensitivity of the Southern blot hybridization for in vivo analysis, known amounts of DNA were used to spike the reaction. As shown in Figure  7d and e, the sensitivity of the Southern blot was limited to 12.5 ng of plasmid DNA in 30 mg of genomic DNA. We next performed Southern blot analysis of a series of tissues harvested from the immunocompetant mice to determine the correlation between PCR and Southern blotting results. As shown in Figure 7f , only the positive control could be detected on the autoradiogram indicating that the quantity of plasmid in the samples was below the level of detection of the assay.
EGFR antisense DNA is localized to the tumor but is not present in the gonads following intratumoral administration
Using the more sensitive PCR method, we were able to detect EGFR antisense DNA in all tissues at each time point following a single intramuscular injection. Proces- EGFR antisense PCR β-Actin PCR Figure 5 Distribution of EGFR antisense plasmid DNA in genomic DNA plus plasmid DNA extracted from tissues. Representative ethidium bromide-stained agarose gels of PCR reaction products from representative organs harvested at 1 month. Plasmid DNA was detected at the injection site (5/6 mice), lung (4/6 mice) and muscle contralateral to the site of injection (4/6 mice). Ethidium bromidestained gels of b-actin in the corresponding samples show that the DNA subjected to PCR analysis was of good quality. sing of the tissues for use in PCR does not distinguish extracellular from intracellular DNA. Thus, using PCR, plasmid DNA in the circulation would be indistinguishable from plasmid DNA localized to the intracellular compartment. As shown in Figure 8 , in a separate experiment, intratumoral administration of fluoresceinlabeled EGFR antisense DNA resulted in detection of foreign DNA in the tumor, but not in the gonads (ovaries) at any time point up to 2 weeks following a single intratumoral injection.
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Discussion
In support of a phase I clinical trial of an EGFR antisense-liposome complex administered via intratumoral injection to head and neck cancer patients, we conducted a series of studies to determine the tissue distribution in multiple organs from mice after a single high-dose intramuscular injection. Two different strategies were employed to isolate nucleic acid from the tissues, resulting in PCR assays characterized by different sensitivities. Optical imaging studies and DNA integration experiments to determine the functional consequence of the persistence of the EGFR antisense DNA detected using the highly sensitive PCR approach, complemented these PCR assays. The inability to image the EGFR antisense gene in tissues distant from the injection site suggests that the more sensitive PCR method may be detecting extracellular DNA. In the absence of evidence demonstrating integration of the foreign DNA into the host genome in vivo, the biologic significance of the PCR findings using the more sensitive method remains uncertain.
Organ toxicity or inadequate delivery to the tumor cells often limits formulations delivered systemically. Head and neck cancers are generally accessible to intralesional routes of administration, thereby increasing the likelihood of delivering the compound to the tumor and limiting toxic effects to organs distant from the injection site.
Several gene therapy trials have been reported in HNSCC patients, all of which administered the gene by direct injection into the tumor. The majority of studies have attempted to deliver wild-type p53 using adenoviral vectors. Phase I and phase II trials using a recombinant p53 adenovirus (Ad-p53) demonstrated little toxicity and encouraging results in the adjuvant setting. 15 In combination with chemotherapy, several trials have administered a replication-selective adenovirus (ONYX-015) designed to preferentially replicate in and lyse p53-deficient cancer cells while sparing normal cells. 16, 17 These phase II studies demonstrated objective responses at the site of injection, in patients with multiple lesions. However, there was no evidence of tumor regression at uninjected sites. 17 Cationic liposomes have been used in the phase I setting in HNSCC to deliver a variety of genes including HLA-B7, IL-2 and ElA. [18] [19] [20] We used the cationic derivative of cholesterol, DC-Chol. These cationic liposomes were mixed with plasmid DNA encoding an EGFR antisense gene. DC-chol has been used to deliver genes successfully to cells in preclinical models as well as clinical studies. [21] [22] [23] [24] However, little is known regarding the tissue distribution of a gene when injected into HNSCC tumors. Random integration of the foreign gene in reproductive tissues could have repercussions on future generations. To date, there have been no reports of gametic integration in either preclinical studies or in the setting of clinical trials. However, in the absence of uniform methods with defined sensitivities to examine distant tissues for evidence of foreign DNA, there is inadequate information regarding the distribution of intralesional liposomal gene therapy.
The vast majority of genes utilized for therapeutic applications have been expressed under the control of an RNA polymerase II type promoter. We elected to place our EGFR antisense sequence under the control of an RNA polymerase III promoter to optimize expression of the transgene in vivo. Several studies have examined the expression of small, potentially therapeutic RNA using the U6 small nuclear RNA promoter. 25, 26 This is the first report investigating the tissue distribution of a gene expressed under the control of the U6 promoter. There- fore, the widespread distribution and persistent detection of the EGFR transgene in tissues distant from the injection site may be due, in part, to this strong promoter.
One of the greatest challenges in gene transfer for cancer therapy is the lack of specific vectors to target tumors selectively. This leads to the unintentional delivery of target genes to all tissues of the body. Theoretically, intratumoral delivery should lead to less widespread distribution of DNA compared with systemic approaches. The results of the present study suggest that intramuscular injection of a liposomal DNA preparation can be detected in organs distant from the injection site. In the absence of a widely accepted immunocompetant model of human HNSCC, we selected an intramuscular route of delivery since intratumoral delivery in head and neck cancer patients is accompanied by injection into the surrounding musculature. Widespread distribution of plasmid DNA has been reported following intramuscular administration. 27 Technical details, including the intramuscular injection approach (longitudinal versus parallel), have been found to influence transfection efficiency in an animal model where expression of the transfected gene persisted for up to 1 month. 28 In another study, plasmid DNA persisted for at least 19 months after injection into skeletal muscle. 29 The PCR assay is a highly efficient gene amplification procedure that has been increasingly applied to the safety assessment of gene therapy. However, there have been no consistent requirements for assay sensitivity in the development of intratumoral gene therapy approaches. Since the death of a patient treated on a gene therapy protocol, in 1999 regulatory agencies have attempted to standardize the methods used to evaluate organs for the presence of foreign DNA. We utilized two PCR methods, one of which was 83-fold more sensitive than the other method at detecting the EGFR antisense DNA. Our findings demonstrate that the ability to detect the gene, directly correlates with the sensitivity of the method employed. Using the less-sensitive approach, we found that DNA remained at the injection site for up to 1 week following a single injection and was not detected in any organ other than the injection site by 7 days. Plasmid DNA was not detected in the plasma even at the 48 hours time point indicating that there was no systemic circulation of the antisense DNA. In contrast, the more sensitive method demonstrated EGFR antisense DNA in all organs of selected mice examined up to 1 month following a single treatment. To determine the biologic significance of the PCR results, we analyzed the gonadal tissue with optical imaging techniques and were unable to detect the foreign DNA at any time point. The ability to detect labeled DNA on histology may reflect the relative sensitivity of this method compared with a PCR assay.
A potential drawback of PCR-based assays is the inability to distinguish between foreign DNA that has been integrated into the genome from DNA that remained as episomal entities within cells. To overcome this obstacle, investigators have used DpnI or MboI restriction enzymes that cleave methylation sites in plasmid DNA. These sites are lost on integration of the plasmid in the genome of cells because of the action of DNA repair enzymes, thereby allowing the distinction between incorporated versus episomal DNA. 30 We were unable to demonstrate integration of the EGFR antisense gene into the host genome at the injection site at all time points examined. Southern blot hybridization at 24 hours postinjection in vivo demonstrated the same pattern as that obtained from restriction enzyme digestion of the pNGVL-1-EGFR antisense plasmid DNA. This suggests that the plasmid existed as episomal DNA in the cells at 1 day. However, since Southern blot analysis is less sensitive than a PCR-based assay, an integration event cannot be excluded. Integrated plasmid was not detected at any time point. Although the frequency of plasmid DNA integration after transfection of cells in vitro is low, integration and replication of plasmid have been observed in vivo. 31 Intramuscular administration of plasmid DNA has been shown to result in episomal plasmid retention for up to 19 months at the site of injection. 32 However, the kinetics of incorporation of plasmid DNA into cells following intravenous, intralesional or subcutaneous injections probably varies. In one study, plasmid DNA injected intravenously was cleared from the vascular space in less than 5 minutes and was undetectable after an hour. 10 While intact plasmid DNA was retained in various tissues at 24 hours, no intact plasmid DNA could be detected after 7 days. 10 Intradermal injection of up to 2 mg of plasmid DNA in pigs demonstrated that while most organs contained the plasmid DNA, integration into the host genome was not found. 33 The functional significance of the persistence of plasmid DNA, in the absence of integration, remains unknown. The results of the present study suggest that the requirement for an assay that detects fewer than 500 molecules in 1 mg of genomic DNA may overestimate the biologic consequences of foreign DNA distribution. It is likely that transgene expression in specific tissues depends on the dose of DNA per injection, the dosing frequency, the promoter element used and the route of administration.
